Dr. Danny Markabawi, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 209
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NJ license 25MA11534400 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cooper University Hospital Camden, NJ
- Cape Regional Medical Center Inc Cape May Court House, NJ
- Holy Redeemer Hospital and Medical Center Meadowbrook, PA
Medical groups
- Cmc Department of Medicine Group PA (478 clinicians)
- Redeemer Cancer Care Physicians Network, LLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 209
- Services billed
- 523
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 164 | 117 |
| Established patient office or other outpatient visit, 20-29 minutes | 97 | 69 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 32 | 29 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 20 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Camden, NJ | 182 |
| Eliquis (apixaban) Other prescribers in Camden, NJ | 82 |
| Anastrozole Other prescribers in Camden, NJ | 73 |
| Exemestane | 63 |
| Ondansetron Odt (ondansetron) Other prescribers in Camden, NJ | 35 |
| Prochlorperazine Maleate Other prescribers in Camden, NJ | 22 |
| Tamoxifen Citrate Other prescribers in Camden, NJ | 21 |
| Duloxetine Hcl Other prescribers in Camden, NJ | 20 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Camden, NJ | 19 |
| Verzenio (abemaciclib) | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $68.98 in total to this clinician.
| Eisai Inc. | $33.57 |
|---|---|
| Daiichi Sankyo Inc. | $18.79 |
| Caris Mpi, Inc. | $16.62 |
| Food and Beverage | $68.98 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $130,425 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast …
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.